Skip to main content
SpringerLink
Log in

New and Future Therapies

  • Chapter
  • First Online:
Managing Diabetes

  • 1448 Accesses

Abstract

The available treatments for diabetes all have limitations, either because of side effects (particularly weight gain and hypoglycemia) or due to contraindications; hence there has been an increased emphasis on the development of newer and more effective agents for lowering glucose.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pfutzner A, Mann AE, Steiner SS. Technosphere/insulin: a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Techol Ther. 2002;509–594.

    Google Scholar 

  2. Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice-daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375:2244–2253.

    Google Scholar 

  3. Kling J. Dreamboat sinks prospects for fast approval of inhaled insulin. Nature Biotech. 2011;29:175–176.

    Google Scholar 

  4. Bailey CJ, Gross LJ, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223–2233.

    Google Scholar 

  5. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015–2022.

    Google Scholar 

  6. Nauck M, Del Prato S, Rohwedder K, Theuerkauf A, Langkilde AM, Parikh S. Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin: 2-year results. Poster presented at the 71st Scientific Sessions of the American Diabetes Association, June 24–28, 2011; San Diego, California.

    Google Scholar 

  7. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;3322:2217–2224.

    Google Scholar 

  8. Aires I, Calado J. BI-10773, a sodium-glucose cotransporter 2 inhibitor for the potential oral treatment of type 2 diabetes mellitus. Curr Opin Investig Drugs. 2010;11:1182–1190.

    Google Scholar 

  9. Anderson SL, Marrs JC. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother. 2012;46:590–598.

    Google Scholar 

  10. Gregoire FM, Zhang F, Clarke HJ, et al. MBX-102/JNJ39659100, a novel peroxisome proliferatoractivated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009;23:975–988.

    Google Scholar 

  11. INT131-004 Study Group. Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with type 2 diabetes. J Diabetes Complications. 2011;25:151–158.

    Google Scholar 

  12. Higgins LS, DePaoli AM. Selective peroxisome proliferator-activated receptor γ (PPARγ) modulation as a strategy for safer therapeutic PPARg activation. Am J Clin Nutr. 2010;91(suppl):267S–272S.

    Google Scholar 

  13. Balakumar P, Rose M, Subrahmanya S, et al. PPAR dual agonists: Are they opening Pandora’s box? Pharmacological Res. 2007;56:91–98.

    Google Scholar 

  14. Lecka-Czernik B. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus. IDrugs. 2010;11:793–807.

    Google Scholar 

  15. Matschinsky FM, Porte D Jr. Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics. F1000 Med Rep. 2010;2:43–48.

    Google Scholar 

  16. Sorensen H, Brand CL, Neschan S, et al. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes. 2006;55:2843–2848.

    Google Scholar 

  17. Finkel T, Deng CX, Mostoslavsky R, et al. Recent progress in the biology and physiology of sirtuins. Nature. 2009;460:587–591.

    Google Scholar 

  18. Banks AS, Kon N, Knight C, et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 2008;8:333–341.

    Google Scholar 

  19. Haigis MC, Mostoslavsky R, Haigis KM, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell. 2006;126:941–954.

    Google Scholar 

  20. Lim CS. SIRT1: tumor promoter or tumor suppressor? Med Hypotheses. 2006;67:341–344.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Royal Liverpool University Hospital, Liverpool, UK

    Santosh Shankarnarayan

  2. Glan Clwyd Hospital, Bodelwyddan, UK

    Gayatri Sreemantula

Authors
  1. Santosh Shankarnarayan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gayatri Sreemantula
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. General Medicine/Diabetes/Endocrinology, Royal Liverpool University Hospital, Liverpool, United Kingdom

    Jiten Vora

  2. Department of General Medicine, Llandough Hospital, Penarth, United Kingdom

    Marc Evans

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Healthcare

About this chapter

Cite this chapter

Shankarnarayan, S., Sreemantula, G. (2012). New and Future Therapies. In: Vora, J., Evans, M. (eds) Managing Diabetes. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-81-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-908517-81-4_5

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-908517-57-9

  • Online ISBN: 978-1-908517-81-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation